Zollinger-Ellison syndrome - Revision history

Ostermayer: Prepared the page for translation

2026-01-05T00:04:17Z

Prepared the page for translation

← Older revision		Revision as of 00:04, 5 January 2026
Line 1:		Line 1:
			<languages/>
			<translate>

	==Background==		==Background==

	*Also known as "S-E syndrome"		*Also known as "S-E syndrome"
	*Caused by secretion of gastrin by duodenal/pancreatic neuroendocrine tumors (gastrinomas) —> high gastric acid output by parietal cells		*Caused by secretion of gastrin by duodenal/pancreatic neuroendocrine tumors (gastrinomas) —> high gastric acid output by parietal cells
	*Associated with [[peptic ulcers]] and [[diarrhea]]		*Associated with [[Special:MyLanguage/peptic ulcers\|peptic ulcers]] and [[Special:MyLanguage/diarrhea\|diarrhea]]
	*60-90% malignant <ref> Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411. doi: 10.1097/00005792-200011000-00004. PMID: 11144036.</ref>, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.		*60-90% malignant <ref> Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411. doi: 10.1097/00005792-200011000-00004. PMID: 11144036.</ref>, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.


	==Clinical Features==		==Clinical Features==
	*[[Hematemesis]]
	*Chronic [[diarrhea]] that is responsive to [[PPI]]s		*[[Special:MyLanguage/Hematemesis\|Hematemesis]]
	*[[Gastroesophageal reflux disease]]		*Chronic [[Special:MyLanguage/diarrhea\|diarrhea]] that is responsive to [[Special:MyLanguage/PPI\|PPI]]s
			*[[Special:MyLanguage/Gastroesophageal reflux disease\|Gastroesophageal reflux disease]]
	*Steatorrhea		*Steatorrhea
	*Weight loss		*Weight loss
	*Postprandial [[abdominal pain]]		*Postprandial [[Special:MyLanguage/abdominal pain\|abdominal pain]]
	*[[Nausea]]		*[[Special:MyLanguage/Nausea\|Nausea]]
	*Wheezes on auscultation		*Wheezes on auscultation
	*Evidence of malnourishment and decreased oral intake		*Evidence of malnourishment and decreased oral intake


	==Differential Diagnosis==		==Differential Diagnosis==

			</translate>
	{{Abdominal Pain DDX Epigastric}}		{{Abdominal Pain DDX Epigastric}}
			<translate>
			</translate>
	{{UGIB DDX}}		{{UGIB DDX}}
			<translate>


	==Evaluation==		==Evaluation==


	===Workup===		===Workup===


	===Diagnosis===		===Diagnosis===

	*Fasting serum gastrin concentration (>10x upper limit of normal) in the presence of gastric pH <2 is diagnostic		*Fasting serum gastrin concentration (>10x upper limit of normal) in the presence of gastric pH <2 is diagnostic
	*If findings not diagnostic for ZES, will require secretin stimulation test		*If findings not diagnostic for ZES, will require secretin stimulation test


	==Management==		==Management==

	*Proton-Pump Inhibitors		*Proton-Pump Inhibitors
	*Somatostatin analog (Octreotide) if no improvement		*Somatostatin analog (Octreotide) if no improvement
	**Direct inhibition of gastric secretion		**Direct inhibition of gastric secretion
	*Surgical resection		*Surgical resection


	==Disposition==		==Disposition==
Line 43:		Line 63:

	==References==		==References==

	<references/>		<references/>


	[[Category:GI]]		[[Category:GI]]
			</translate>

Rossdonaldson1: /* Differential Diagnosis */

2022-12-07T23:37:17Z

Differential Diagnosis

← Older revision		Revision as of 23:37, 7 December 2022
Line 17:		Line 17:

	==Differential Diagnosis==		==Differential Diagnosis==
			{{Abdominal Pain DDX Epigastric}}
			{{UGIB DDX}}

	==Evaluation==		==Evaluation==

Rossdonaldson1: /* Background */

2022-12-07T23:36:23Z

Background

← Older revision		Revision as of 23:36, 7 December 2022
Line 2:		Line 2:
	*Also known as "S-E syndrome"		*Also known as "S-E syndrome"
	*Caused by secretion of gastrin by duodenal/pancreatic neuroendocrine tumors (gastrinomas) —> high gastric acid output by parietal cells		*Caused by secretion of gastrin by duodenal/pancreatic neuroendocrine tumors (gastrinomas) —> high gastric acid output by parietal cells
	*Associated with peptic ulcers and diarrhea		*Associated with [[peptic ulcers]] and [[diarrhea]]
	*60-90% malignant <ref> Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411. doi: 10.1097/00005792-200011000-00004. PMID: 11144036.</ref>, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.		*60-90% malignant <ref> Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411. doi: 10.1097/00005792-200011000-00004. PMID: 11144036.</ref>, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.

Rossdonaldson1: /* Clinical Features */

2022-12-07T23:35:35Z

Clinical Features

← Older revision		Revision as of 23:35, 7 December 2022
Line 6:		Line 6:

	==Clinical Features==		==Clinical Features==
	*Hematemesis		*[[Hematemesis]]
	*Chronic diarrhea that is responsive to ~~PPIs~~		*Chronic [[diarrhea]] that is responsive to [[PPI]]s
	*[[Gastroesophageal reflux disease]]		*[[Gastroesophageal reflux disease]]
	*Steatorrhea		*Steatorrhea
	*Weight loss		*Weight loss
	*Postprandial abdominal pain		*Postprandial [[abdominal pain]]
	*Nausea		*[[Nausea]]
	*Wheezes on auscultation		*Wheezes on auscultation
	*Evidence of malnourishment and decreased oral intake		*Evidence of malnourishment and decreased oral intake

Kennybroccoli: /* Background */

2022-12-07T06:00:09Z

Background

← Older revision		Revision as of 06:00, 7 December 2022
Line 1:		Line 1:
	==Background==		==Background==
	*Also known as "S-E syndrome"		*Also known as "S-E syndrome"
	*gastric ~~neuroendocrine malignancy results in hypersecretion of hydrochloric~~ acid by parietal cells		*Caused by secretion of gastrin by duodenal/pancreatic neuroendocrine tumors (gastrinomas) —> high gastric acid output by parietal cells
	*Associated with peptic ulcers and diarrhea		*Associated with peptic ulcers and diarrhea
	*60% malignant, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.		*60-90% malignant <ref> Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411. doi: 10.1097/00005792-200011000-00004. PMID: 11144036.</ref>, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.

	==Clinical Features==		==Clinical Features==
	*Hematemesis		*Hematemesis
	*Chronic diarrhea		*Chronic diarrhea that is responsive to PPIs
			*[[Gastroesophageal reflux disease]]
	*Steatorrhea		*Steatorrhea
			*Weight loss
	*Postprandial abdominal pain		*Postprandial abdominal pain
	*Nausea		*Nausea
Line 21:		Line 23:

	===Diagnosis===		===Diagnosis===
			*Fasting serum gastrin concentration (>10x upper limit of normal) in the presence of gastric pH <2 is diagnostic
			*If findings not diagnostic for ZES, will require secretin stimulation test

	==Management==		==Management==

Erdojjones: /* Clinical Features */

2022-11-01T23:30:31Z

Clinical Features

← Older revision		Revision as of 23:30, 1 November 2022
Line 8:		Line 8:
	*Hematemesis		*Hematemesis
	*Chronic diarrhea		*Chronic diarrhea
			*Steatorrhea
	*Postprandial abdominal pain		*Postprandial abdominal pain
	*Nausea		*Nausea

Erdojjones: /* Management */

2022-11-01T23:29:17Z

Management

← Older revision		Revision as of 23:29, 1 November 2022
Line 22:		Line 22:

	==Management==		==Management==
			*Proton-Pump Inhibitors
			*Somatostatin analog (Octreotide) if no improvement
			**Direct inhibition of gastric secretion
			*Surgical resection

	==Disposition==		==Disposition==

Rossdonaldson1 at 21:04, 31 August 2022

2022-08-31T21:04:32Z

← Older revision		Revision as of 21:04, 31 August 2022
Line 35:		Line 35:
	==References==		==References==
	<references/>		<references/>


			[[Category:GI]]

Rossdonaldson1: /* Background */

2022-08-31T21:02:26Z

Background

← Older revision		Revision as of 21:02, 31 August 2022
Line 1:		Line 1:
	==Background==		==Background==
	*~~aka~~ S-E syndrome		*Also known as "S-E syndrome"
	*gastric neuroendocrine malignancy results in hypersecretion of hydrochloric acid by parietal cells		*gastric neuroendocrine malignancy results in hypersecretion of hydrochloric acid by parietal cells
	*Associated with peptic ulcers and diarrhea		*Associated with peptic ulcers and diarrhea

Rossdonaldson1 at 20:50, 27 February 2021

2021-02-27T20:50:27Z

← Older revision		Revision as of 20:50, 27 February 2021
Line 2:		Line 2:
	*aka S-E syndrome		*aka S-E syndrome
	*gastric neuroendocrine malignancy results in hypersecretion of hydrochloric acid by parietal cells		*gastric neuroendocrine malignancy results in hypersecretion of hydrochloric acid by parietal cells
			*Associated with peptic ulcers and diarrhea
			*60% malignant, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.

	==Clinical Features==		==Clinical Features==